Hyperkalemia is a potential life-threatening condition among chronic kidney disease (CKD) patients. Available estimates of the burden of this alteration in CKD are mainly derived from large administrative databases. Since K measurements in patients in these databases are often dictated by clinical reasons, longitudinal studies including pre-planned measurements of potassium independently of clinical complication/symptoms may produce more reliable estimates of the frequency and the risk factors underlying hyperkalemia in CKD patients. We estimated the prevalence and the incidence of hyperkalemia in a longitudinal study in 752 stages 2–5 CKD patients lasting 3 years and including up to seven pre-planned assessment of key biochemical measurements including K. At baseline, 203 out of 752 patients (27%) had serum K > 5.0 mM/L and 33% had acidosis (HCO3 ≤ 22 mmol/L). Among those without hyperkalemia at baseline (n = 549), 284 patients developed this alteration across the 3-year follow-up. The point prevalence of hyperkalemia rose from 27% (baseline) to 30% (last visit) (P = 0.001). In a multivariate model, hyperkalemia at baseline [odds ratio (OR):7.29, 95% CI 5.65–9.41, P < 0.001], venous bicarbonate levels [OR (1 mmol/l): 0.92, 0.89–0.96, P < 0.001], eGFR [OR (1 ml/min/1.73m2): 0.98, 0.97–0.99, P < 0.001], use of ACE inhibitors (OR: 1.68, 1.28–2.19, P < 0.001) and angiotensin II antagonists (OR: 1.30, 1.01–1.68, P = 0.045) were related to hyperkalemia over time. Of note, venous bicarbonate levels emerged as an independent risk factor of hyperkalemia over time also in a separate analysis of patients with and without hyperkalemia at baseline. In a cohort of CKD patients including pre-planned measurements of K, 27% of patients had hyperkalemia. Metabolic acidosis and the use of drugs interfering with renin–angiotensin system were the strongest modifiable risk factors for this potentially life-threatening alteration in CKD in longitudinal analyses in the whole study cohort and in patients developing de novo hyperkalemia over time.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Availability of data and material
Data will be available at request.
Palmer BF, Clegg DJ (2017) Treatment of abnormalities of potassium homeostasis in CKD. Adv Chronic Kidney Dis 24:319–324. https://doi.org/10.1053/j.ackd.2017.06.001
Gilligan S, Raphael KL (2017) Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes. Adv Chronic Kidney Dis 24:315–318. https://doi.org/10.1053/j.ackd.2017.06.004
Kovesdy CP (2016) Epidemiology of hyperkalemia: an update. Kidney IntSuppl 6:3–6. https://doi.org/10.1016/j.kisu.2016.01.002
Luo J, Brunelli SM, Jensen DE, Yang A (2016) Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am SocNephrol 11:90–100. https://doi.org/10.2215/CJN.01730215
Thomsen RW, Nicolaisen SK, Hasvold P et al (2018) Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study. Nephrol Dial Transplant 33:1610–1620. https://doi.org/10.1093/ndt/gfx312
Gasparini A, Evans M, Barany P et al (2019) Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. Nephrol Dial Transplant 34:1534–1541. https://doi.org/10.1093/ndt/gfy249
Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W et al (2017) Impact of admission serum potassium on mortality in patients with chronic kidney disease and cardiovascular disease. QJM AnInt J Med 110:713–719. https://doi.org/10.1093/qjmed/hcx118
Weiner ID, Wingo CS (1998) Hyperkalemia: a potential silent killer. J Am SocNephrol 9:1535–1543
Perazella MA (2000) Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 109:307–314. https://doi.org/10.1016/S0002-9343(00)00496-4
Allon M (2014) Disorders of potassium metabolism. In: Gilbert SJ, Daniel E (eds) National Kidney foundation primer on kidney diseases, 6th edn. Weiner Elsevier, pp 90–99
Palmer BF (2020) Potassium binders for hyperkalemia in chronic kidney disease—diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis. Mayo ClinProc 95:339–354. https://doi.org/10.1016/j.mayocp.2019.05.019
Collins AJ, Pitt B, Reaven N et al (2017) Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol 46:213–221. https://doi.org/10.1159/000479802
Einhorn LM, Zhan M, Hsu VD et al (2009) The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169:1156. https://doi.org/10.1001/archinternmed.2009.132
Epstein M (2016) Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney IntSuppl 6:20–28. https://doi.org/10.1016/j.kisu.2016.01.004
Levin A, Stevens PE, Bilous RW et al (2013) Notice. Kidney IntSuppl 3:1. https://doi.org/10.1038/kisup.2012.73
James PA, Oparil S, Carter BL et al (2014) 2014 Evidence-based guideline for the management of high blood pressure in adults. JAMA 311:507. https://doi.org/10.1001/jama.2013.284427
Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am CollCardiol 70:776–803. https://doi.org/10.1016/j.jacc.2017.04.025
(2019) 10. Cardiovascular disease and risk management: Standards of medical care in diabetes 2019. Diabetes Care. https://doi.org/10.2337/dc19S010
Chang AR, Sang Y, Leddy J et al (2016) Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension 67:1181–1188. https://doi.org/10.1161/HYPERTENSIONAHA.116.07363
Hu J-R, Coresh J (2017) The public health dimension of chronic kidney disease: what we have learnt over the past decade. Nephrol Dial Transplant 32:i1113–i1120. https://doi.org/10.1093/ndt/gfw416
Lazich I, Bakris GL (2014) Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. SeminNephrol 34:333–339. https://doi.org/10.1016/j.semnephrol.2014.04.008
Latts LM, Reaven NL, Funk SE et al (2015) Hyperkalemia Is highly prevalent in patients with cardiorenal comorbidities compared to patients without these comorbidities. Value Heal 18:A135. https://doi.org/10.1016/j.jval.2015.03.786
Kashihara N, Kohsaka S, Kanda E et al (2019) Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int Reports 4:1248–1260. https://doi.org/10.1016/j.ekir.2019.05.018
Sarafidis PA, Blacklock R, Wood E et al (2012) Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am SocNephrol 7:1234–1241. https://doi.org/10.2215/CJN.01150112
Hayes J, Kalantar-Zadeh K, Lu JL et al (2012) Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron ClinPract 120:c8–c16. https://doi.org/10.1159/000329511
Zoccali C, Leonardis D, Enia G et al (2008) The MAURO study: multiple intervention and audit in renal diseases to optimize care. J Nephrol 21:20–22
Leonardis D, Mallamaci F, Enia G et al (2012) The MAURO study: Baseline characteristics and compliance with guidelines targets. J Nephrol 25:1081–1090
Levey AS (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461. https://doi.org/10.7326/0003-4819-130-6-199903160-00002
Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K (2012) Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am SocNephrol 8:1234–1241
Hanley JA, Negassa A, de Edwardes MDB, Forrester JE (2003) Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 157:364–375. https://doi.org/10.1093/aje/kwf215
Bianchi S, Aucella F, De Nicola L et al (2019) Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol 32:499–516. https://doi.org/10.1007/s40620-019-00617-y
Provenzano M, Minutolo R, Chiodini P, Bellizzi V, Nappi F, Russo D, Borrelli S, Garofalo C, Iodice C, De Stefano T, Conte G, Heerspink HJL, De Nicola L (2018) Competing-risk analysis of death and end stage kidney disease by hyperkalaemia status in non-dialysis chronic kidney disease patients receiving stable nephrology care. J Clin Med 7:499. https://doi.org/10.3390/jcm7120499
Sousa AGP, de Cabral JVS, El-Feghaly WB et al (2016) Hyporeninemichypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management. World J Diabetes 7:101. https://doi.org/10.4239/wjd.v7.i5.101
Chatterjee R, Yeh H-C, Edelman D, Brancati F (2011) Potassium and risk of type 2 diabetes. Expert Rev EndocrinolMetab 6:665–672. https://doi.org/10.1586/eem.11.60
Ben Salem C, Badreddine A, Fathallah N et al (2014) Drug-induced hyperkalemia. Drug Saf 37:677–692. https://doi.org/10.1007/s40264-014-0196-1
Burnell JM, Villamil MF, Uyeno BT, Scribner BH (1956) The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium. J Clin Invest 35:935–939. https://doi.org/10.1172/JCI103352
Conflicts of interest/competing interest
No conflict/competing interest is related to this manuscript;
Human and animal rights
The study protocol was approved by the Ethical Committee of our Institution.
Informed consent was obtained from each participant.
Consent for publication
All co-authors agreed to publish this paper.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Panuccio, V., Leonardis, D., Tripepi, R. et al. Epidemiology of hyperkalemia in CKD patients under nephrological care: a longitudinal study. Intern Emerg Med (2021). https://doi.org/10.1007/s11739-021-02653-8
- Chronic kidney disease
- Longitudinal study
- ACE inibitors
- Angiotensin II receptor blockers